What is the 13F Pro Quality Score for PROF?

13F Pro ranks Profound Medical Corp. (PROF) on the 13F Pro Quality Score, a 0–100 composite of 32 fundamental signals including return on invested capital, free cash flow consistency, balance-sheet strength, earnings quality, growth durability, and valuation discipline. The score refreshes after each 10-K and 10-Q filing on SEC EDGAR. View PROF's current score at https://13fpro.ai/research/PROF (free sign-up required for the full ranking).

Which hedge funds own the most PROF stock?

Based on the most recent Form 13F-HR filings on SEC EDGAR, the largest reported institutional holders of PROF include FIL Ltd, GAGNON SECURITIES, Timelo Investment Management. Holdings are reported quarterly within 45 days of quarter-end and updated on https://13fpro.ai/research/PROF as soon as new 13F filings post.

Where does 13F Pro source PROF data?

All Profound Medical Corp. fundamentals and ownership data come directly from SEC EDGAR. Profound Medical Corp. files with the SEC under CIK 1628808. 13F Pro ingests XBRL financial facts from 10-K and 10-Q filings, Form 13F-HR institutional holdings, and Form 4 insider transactions, with no third-party rewrites or estimates.

What sector is PROF in?

Profound Medical Corp. (PROF) is classified in the Healthcare sector. 13F Pro publishes sector-level fund flow analysis and quality leaders at https://13fpro.ai/research/sector/healthcare.

How often is PROF research updated on 13F Pro?

PROF's fundamentals refresh within hours of each new 10-K or 10-Q filing on SEC EDGAR. Institutional ownership updates after each quarterly 13F filing window. Insider transactions update after each Form 4 filing. The 13F Pro Quality Score recalculates after every fundamentals refresh.

Profound Medical Corp.(PROF)Stock Analysis

AI analysis on 2,800+ stocks →Deep AI analysis on 2,800+ stocks →

Healthcare →Nasdaq

Institutional-grade research for retail investors

SEC EDGAR: CIK 1628808 PROF stock profile & AI dashboard →

13F Pro Quality Score

Not in ranked universe

Below size threshold

Quality rankings require at least $50M annual revenue or $250M total assets to filter out micro-caps and shell companies. This company reported $16.1M in revenue.

Financial data, filings, and institutional holdings below are still tracked in full — only the proprietary quality composite is unavailable for this name.

PROF Stock Analysis & AI Quality Score

AI stock analysis and institutional research for Profound Medical Corp. (PROF), a Healthcare sector company. PROF is not currently included in 13F Pro's AI-ranked quality universe — quality rankings require at least $50m annual revenue or $250m total assets to filter out micro-caps and shell companies. this company reported $16.1m in revenue. Based on the latest XBRL financial filings (Q1 2026), Profound Medical Corp. reports quarterly revenue of $5.3M, net income of $-7.1M, free cash flow of $-8.6M. Top institutional holders of PROF by reported 13-F value include FIL Ltd, GAGNON SECURITIES, Timelo Investment Management, based on the most recent SEC filings. PROF trades on the Nasdaq exchange and files with the SEC under CIK 1628808. 13F Pro's AI research platform runs 10 specialized AI analysts — value, growth, momentum, macro, and activist specialists — that debate PROF daily and publish AI-generated analysis with cited SEC sources. The platform aggregates historical XBRL financial facts, 10-Q and 10-K filings, insider Form 4 transactions, and institutional 13-F holdings for Profound Medical Corp. directly from SEC EDGAR.

Revenue

Q1 2026

$5.3M

Net Income

Q1 2026

$-7.1M

Free Cash Flow

Q1 2026

$-8.6M

D/E Ratio

Q1 2026

0.15

Revenue & Net Income

Earnings Per Share

Key Financials Over Time

Export Financial Table · Pro+

Revenue

+48.4% YoY

$10.7MFY 2024

FY23 $7.2MFY24 $10.7M

Net Income

+1.8% YoY

$-27.8MFY 2024

FY23 $-28.3MFY24 $-27.8M

Operating Income

-15.4% YoY

$-33.1MFY 2024

FY23 $-28.7MFY24 $-33.1M

EPS (Diluted)

-16.4% YoY

$1.12FY 2024

FY23 $1.34FY24 $1.12

Total Assets

+59.8% YoY

$70.2MFY 2024

FY23 $44.0MFY24 $70.2M

Total Debt

-30.5% YoY

$6.4MFY 2024

FY23 $9.2MFY24 $6.4M

Op. Cash Flow

-3.7% YoY

$-23.5MFY 2024

FY23 $-22.6MFY24 $-23.5M

Metric	FY 2024	FY 2023
Revenue	$10.7M +48.4%	$7.2M
Net Income	$-27.8M +1.8%	$-28.3M
Operating Income	$-33.1M -15.4%	$-28.7M
EPS (Diluted)	$1.12 -16.4%	$1.34
Total Assets	$70.2M +59.8%	$44.0M
Total Debt	$6.4M -30.5%	$9.2M
Operating Cash Flow	$-23.5M -3.7%	$-22.6M

AI Insight: PROF Financial Trends

Profound Medical is burning through equity rapidly, though Q4 2025 capital raise stabilized the balance sheet and losses are narrowing.

• Equity collapsed from $60M in Q4 2024 to $32M in Q3 2025, a $28M drawdown in three quarters driven by persistent net losses.

• Net loss improved from -$16M in Q2 2025 to -$7M in Q1 2026, suggesting meaningful reduction in cash burn over four quarters.

• Revenue grew from $2M in Q2 2025 to $6M in Q4 2025, though Q1 2026 slipped back to $5M — trend is uneven.

• Operating cash outflow remains negative every quarter, ranging from -$7M to -$14M, with no quarter approaching breakeven.

⚠ Equity jumped from $32M in Q3 2025 to $66M in Q4 2025, implying a capital raise — dilution risk if burn continues.

⚠ Total debt ticked up to $9M in Q1 2026 from $6M in Q4 2025 — modest but worth monitoring alongside negative operating cash flow.

⚠ Revenue consistency is unproven; Q1 2026 declined sequentially from Q4 2025, raising concern about durable commercial traction.

AI Insight: PROF Ratio Trends

Profound Medical remains deeply unprofitable, though return metrics improved sharply from Q3 2025 lows — leverage stays low at 0.15 D/E.

• ROE improved from -99.3% in Q3 2025 to -47.5% in Q1 2026, suggesting reduced quarterly losses relative to equity.

• Operating margin remained deeply negative at -150.3% in Q1 2026, versus -123.3% in Q4 2025 — a sequential deterioration.

• D/E ratio rose to 0.15 in Q1 2026 from a low of 0.09 in Q4 2025, though leverage remains modest overall.

⚠ Operating margin worsened sequentially to -150.3% in Q1 2026 from -123.3% in Q4 2025 — cost control remains a key concern.

⚠ ROIC of -46.9% in Q1 2026 vs. TTM -55.7% signals persistent capital destruction; trend direction warrants close monitoring.

Get alerted when PROF's score changes

Free account: watchlist tracking, the daily AI brief, and the AI screener.

Passwordless sign-in · Payments by Stripe · Auth by Clerk

Available Research

13F Pro tracks comprehensive data for Profound Medical Corp. including:

SEC EDGAR filings (10-K, 10-Q, 8-K)

XBRL financial facts (revenue, EPS, margins)

Insider transactions (Form 4)

Institutional 13F holdings

Quality rankings (32 signals)

AI analyst debates & daily meetings

Historical financial trends

Peer comparison & sector analysis

Top Institutional Holders of PROF

FIL Ltd
$15.2M2,340,000 sh
GAGNON SECURITIES LLC
$12.6M1,944,324 sh
Timelo Investment Management Inc.
$7.2M1,114,967 sh
ROYCE & ASSOCIATES LP
$7.1M1,116,348 sh
Gagnon Advisors, LLC
$6.2M962,186 sh
LETKO, BROSSEAU & ASSOCIATES INC
$6.1M953,175 sh
Rosalind Advisors, Inc.
$5.4M828,118 sh
Z3 Capital Partners, LLC
$5.3M817,991 sh
MMCAP International Inc. SPC
$4.8M745,152 sh
ARDSLEY ADVISORY PARTNERS LP
$3.7M575,000 sh

Fund	Value	Shares
FIL Ltd	$15.2M	2,340,000
GAGNON SECURITIES LLC	$12.6M	1,944,324
Timelo Investment Management Inc.	$7.2M	1,114,967
ROYCE & ASSOCIATES LP	$7.1M	1,116,348
Gagnon Advisors, LLC	$6.2M	962,186
LETKO, BROSSEAU & ASSOCIATES INC	$6.1M	953,175
Rosalind Advisors, Inc.	$5.4M	828,118
Z3 Capital Partners, LLC	$5.3M	817,991
MMCAP International Inc. SPC	$4.8M	745,152
ARDSLEY ADVISORY PARTNERS LP	$3.7M	575,000

More Healthcare Companies

View all Healthcare →

AAPG

ASCENTAGE PHARMA GROUP INTERNATIONAL

AARD

Aardvark Therapeutics, Inc.

ABBV

AbbVie Inc.

ABCL

AbCellera Biologics Inc.

ABEO

ABEONA THERAPEUTICS INC.

ABOS

Acumen Pharmaceuticals, Inc.

ABPWW

Abpro Holdings, Inc.

ABSI

Absci Corp

Put PROF on your watchlist

Track score changes the day Profound Medical Corp. files with the SEC, follow the hedge funds that own it, screen 2,800+ AI-scored stocks, and get the daily brief — free.

View Pricing

Free tier includes 13F data, economic indicators, and market overview. Pro starts at $6.67/mo (billed annually).

Passwordless sign-in · Payments by Stripe · Auth by Clerk

Popular Research

AAPL

Apple

MSFT

Microsoft

NVDA

NVIDIA

GOOG

Alphabet

AMZN

Amazon

Is PROF a good stock to buy?

13F Pro's AI-powered analysis of Profound Medical Corp. (PROF) draws on SEC EDGAR-sourced fundamentals, institutional 13F holdings, and insider Form 4 transactions in the Healthcare sector (listed on Nasdaq). The 32-signal AI Quality Score, current rank, and full bull/bear verdict for PROF are available on the PROF stock profile dashboard — with the same data, AI insights, ratios, and institutional activity refreshed after every 10-K, 10-Q, 13F, and Form 4 filing.

Which hedge funds own PROF?

Institutional investors are required to disclose their holdings quarterly via SEC Form 13F. 13F Pro aggregates these filings to show which hedge funds, mutual funds, and asset managers are buying or selling PROF. Combined with insider transaction data from Form 4 filings and AI-powered analysis from 10 specialized research agents, 13F Pro provides a comprehensive view of Profound Medical Corp.'s investment landscape.